• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
InNexus Biotechnology Inc. (IXS) - Strategic Analysis Review Product Image

InNexus Biotechnology Inc. (IXS) - Strategic Analysis Review

  • Published: September 2010
  • 20 pages
  • GlobalData

InNexus Biotechnology Inc. (InNexus) is a development stage biotechnology company focused on the development of the next generation of monoclonal antibodies using its Dynamic Cross-linking (DXL) technology. The DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effect or functions and installing new properties into antibodies. The company is developing its first product DXL625, and pursuing additional collaborative development arrangements. It is also preparing for the launch of its second proposed DXL product. It is headquartered in Vancouver, British Columbia of Canada.

InNexus Biotechnology Inc. Key Recent Developments

Jul 01, 2010: InNexus Amends Collaborative Agreement With NCI
Jun 29, 2010: InNexus Develops New Protein For AMD Eye Disorder
May 27, 2010: InNexus Signs Collaboration Agreement With NCI
Mar 23, 2010: InNexus Bio Announces Publication Of DXL625 Data In Journal Of Anti-Cancer Drugs
Jan 05, 2010: InNexus Develops New Psoriasis Product

Our InNexus Biotechnology Inc. - Strategic Analysis Review provides a comprehensive insight READ MORE >



List of Tables
Section 1 - About the Company
InNexus Biotechnology Inc. - Key Facts
InNexus Biotechnology Inc. - Key Employees
InNexus Biotechnology Inc. - Key Employee Biographies
InNexus Biotechnology Inc. - Major Products and Services
InNexus Biotechnology Inc. - History
InNexus Biotechnology Inc. - Company Statement
InNexus Biotechnology Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
InNexus Biotechnology Inc. - Business Description
InNexus Biotechnology Inc. - SWOT Analysis
SWOT Analysis - Overview
InNexus Biotechnology Inc. - Strengths
Strength - Sturdy Research and Development Activities
Strength - Focus on developing monoclonal antibodies (MAb) th
InNexus Biotechnology Inc. - Weaknesses
Weakness - Lack of proper corporate governance
Weakness - Lack of marketable products
InNexus Biotechnology Inc. - Opportunities
Opportunity - Strategic collaboration and agreements
Opportunity - Biotech Focus
Opportunity - Changing Demographics
Opportunity - Emerging markets
InNexus Biotechnology Inc. - Threats
Threat - Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Competitive Pressures
InNexus Biotechnology Inc. - Key Competitors
Section 3 - Company’s Recent Developments
Jul 01, 2010: InNexus Amends Collaborative Agreement With NCI
Jun 29, 2010: InNexus Develops New Protein For AMD Eye Disorder
May 27, 2010: InNexus Signs Collaboration Agreement With NCI
Mar 23, 2010: InNexus Bio Announces Publication Of DXL625 Data In Journal Of Anti-Cancer Drugs
Jan 05, 2010: InNexus Develops New Psoriasis Product
Jul 10, 2009: InNexus, Genhelix Sign Letter of Intent
Section 4 - Appendix
Methodology
About Us
Contact Us
Disclaimer

InNexus Biotechnology Inc. (InNexus) is a development stage biotechnology company focused on the development of the next generation of monoclonal antibodies using its Dynamic Cross-linking (DXL) technology. The DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effect or functions and installing new properties into antibodies. The company is developing its first product DXL625, and pursuing additional collaborative development arrangements. It is also preparing for the launch of its second proposed DXL product. It is headquartered in Vancouver, British Columbia of Canada.

Note: Product cover images may vary from those shown

RELATED PRODUCTS